Molecular Devices Launches Fura-2 QBT Calcium Kit
Molecular Devices® today announced the launch of its Fura-2 QBT Calcium Kit. This new kit combines the calcium indicator Fura-2 with Molecular Devices’ proprietary masking technology to provide a fast, simple and reliable ratiometric fluorescence-based assay for detecting and quantitating changes in intracellular calcium.
Utilising Molecular Devices’ masking technology, the Fura-2 QBT Calcium Kit significantly reduces background fluorescence in media around the cells, enabling researchers to more easily detect signal from within the cell, giving more accurate results. Moreover, the new kit eliminates the need for wash protocols, thus saving time and further improving data quality.
Leveraging the advantages of Fura-2 over other calcium indicators, the dye is excited at two different wavelengths, enabling ratiometric measurement of calcium flux to minimize the impact of assay variances caused by uneven dye loading, leakage or cell density. The Fura-2 QBT Calcium Kit enables detection of the largest signal window available for Fura-2, and allows scientists to interrogate low-density, weakly or non-adherent cells.
Kevin Chance, President of Molecular Devices, commented: “Molecular Devices is fully committed to providing fully validated assay solutions, including tailored reagents and kits. We are continually discussing our customers’ needs in order to develop a range of reagents, instruments and assay protocols that fully support their research. We will be expanding our range of reagents over the coming months delivering not only the complete solution, but individual components for maximum flexibility and convenience.”
The Fura-2 QBT Calcium Kit is validated for use on FlexStation 3 and FLIPR Tetra Systems.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance